文献速递腹部介入US

肝细胞癌消融后局部肿瘤进展:CEUS LI-RADS非放射治疗版2024与改良算法的比较

Local Tumor Progression After Hepatocellular Carcinoma Ablation: CEUS LI-RADS Nonradiation TRA Version 2024 Versus a Modified Algorithm.
PubMed 文献 · Ultrasound Med Biol · 2026-03-20

本回顾性研究纳入2010年6月至2023年6月在本中心接受热消融后行CEUS的肝细胞癌患者,评估CEUS LI-RADS TRA v2024鉴别局部肿瘤进展与术后炎症的表现,并与强调病灶内廓清的改良算法比较。改良LR-TR viable较原版显著提高特异度(58% vs 46%,p=0.008)、AUC(0.77 vs 0.70,p<0.001)和准确率(81% vs 78%,p=0.04),敏感度无显著差异(93% vs 94%,p=1.00)。

要点

  • CEUS LI-RADS TRA v2024鉴别消融后局部肿瘤进展与术后炎症的观察者间一致性良好(κ=0.75)。
  • 改良算法强调病灶内廓清定义病灶内肿瘤存活,特异度58% vs 原版46%(p=0.008)。
  • 改良算法AUC 0.77 vs 原版0.70(p<0.001),准确率81% vs 78%(p=0.04),敏感度无显著差异(93% vs 94%,p=1.00)。

核心结论

  • CEUS LI-RADS TRA在检测消融后肝细胞癌局部肿瘤进展方面表现良好;强调病灶内廓清的改良LR-TR viable算法在不降低敏感度的情况下显著提高特异度。

研究设计与样本

  • 回顾性研究,纳入本中心2010年6月至2023年6月热消融后行CEUS的肝细胞癌患者,共212个CEUS观察病灶(71个术后炎症、141个局部肿瘤进展),比较CEUS LI-RADS TRA v2024与改良算法的诊断表现。

关键影像表现/征象

  • 共2745例肝细胞癌患者接受5612次操作,最终纳入212个CEUS观察病灶。
  • 术后炎症组62例男性、9例女性,年龄60.5±11.5岁;局部肿瘤进展组125例男性、16例女性,年龄58.8±11.5岁。
  • 按CEUS LI-RADS TRA v2024分类,170个(80%)治疗病灶判为LR-TR viable,42个(20%)判为LR-TR equivocal。
  • CEUS LI-RADS TRA分类的观察者间一致性良好(κ=0.75,95%CI:0.69,0.81)。

诊断标准与关键数值

  • 改良算法强调病灶内廓清以定义病灶内肿瘤存活。
  • 改良LR-TR viable vs 原版LR-TR viable:特异度58% vs 46%(p=0.008),AUC 0.77 vs 0.70(p<0.001),准确率81% vs 78%(p=0.04)。
  • 敏感度:改良LR-TR viable 93% vs 原版94%(p=1.00),无显著差异。

临床应用与阅片要点

  • CEUS LI-RADS TRA v2024可用于鉴别消融后肝细胞癌局部肿瘤进展与术后炎症。
  • 作者认为,强调病灶内廓清的改良LR-TR viable算法可提高特异度而不降低敏感度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess the performance of CEUS LI-RADS TRA v2024 in differentiating local tumor progression (LTP) and postprocedural inflammation of ablated hepatocellular carcinoma (HCC), and compare it with a modified version.

METHODS: This retrospective study composed HCC patients who underwent CEUS after thermal ablation from June 2010 to June 2023 in our center. Each image of LTP and postprocedural inflammation was reviewed for CEUS LI-RADS TRA v2024 categorization. A modified CEUS LI-RADS TRA emphasizing intralesional washout in defining intralesional tumor viable was established. The diagnostic performance in distinguishing LTP and postprocedural inflammation of the two algorithms was compared.

RESULTS: Among 2745 HCC patients who underwent 5612 procedures, 212 CEUS observations with 71 postprocedural inflammation (62 males and 9 females, 60.5 ± 11.5 years) and 141 LTPs (125 males and 16 females, 58.8 ± 11.5 years) were enrolled. Interreader agreement for the CEUS LI-RADS TRA category was good (κ = 0.75 [95% CI: 0.69, 0.81]). According to algorithm, 170 (80%) treated lesions were labeled as LR-TR viable and 42 (20%) were assigned as LR-TR equivocal. Emphasizing washout in intralesional viable, the modified LR-TR viable showed significantly greater specificity (58% vs 46%, p = 0.008), AUC (0.77 vs 0.70, p < 0.001) and accuracy (81% vs 78%, p = 0.04) without compromising sensitivity (93% vs 94%, p = 1.00) compared with the original LR-TR viable.

CONCLUSION: CEUS LI-RADS TRA performed well in detecting LTP in ablated HCC. The modified algorithm emphasizing intralesional washout in LR-TR viable significantly improved specificity without compromising sensitivity.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Yao JQ, Guo HL, Zhang XE, et al. Local Tumor Progression After Hepatocellular Carcinoma Ablation: CEUS LI-RADS Nonradiation TRA Version 2024 Versus a Modified Algorithm. Ultrasound Med Biol. 2026. PMID: 41864765. doi:10.1016/j.ultrasmedbio.2026.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。